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ABSTRACT  
The purpose of this study was to develop fast dissolving tablets of Aceclofenac using different concentration of super disintegrants. Fast 
dissolving tablets of Aceclofenac were prepared by dry granulation technique using croscarmellose sodium together with avicel ph as 
superdisintegrants. The porous granules were then compressed in to tablets by direct compression technique. These tablets were evaluated for 
drug content, weight variation, friability, hardness, wetting time and dispersion time. All the formulations showed low weight variation with  
dispersion time less than 90 seconds and rapid in vitro dissolution. The drug content of all the formulations was within the acceptable limits. 
The optimized formulation showed good release profile i.e. maximum drug being released at all-time intervals compared to other trial batches. 
It was concluded that fast dissolving tablets with improved dissolution could be prepared by dry granulation method of tablet. 
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INTRODUCTION 
Oral drug delivery is the most advisable route for drug 
administration among all the routes used for drug delivery. 
Various types of dosage forms are prepared for 
administration of drug via oral route. Solid  dosage  forms  
are  popular  because  of  ease  of administration, self 
medication, accurate  dosage,  pain avoidance and most 
importantly the patient compliance.[1] Dysphagia occurs in 
children due to undeveloped muscular and nervous system, 
geriatric patients suffering from Parkinson’s disease, 
bedridden &mentally ill patients.[2] 
To overcome these problems mouth dissolving tablets are 
the best choice of formulation. These tablets get 
disintegrated or dissolved in buccal cavity avoiding water 
consumption. This is a newer dosage form that gets 
dissolved in saliva in very few seconds. these tablets are also 
known as melt in mouth tablet (MMT), Fast melting tablet 
(FMT), Fast dissolving tablet (FDT), Orally Disintegrated 
tablet (ODT), Rapidly Disintegrated tablet (RDT).[3] 
Aceclofenac,(2-[2-[2-(2,6- dichlorophenyl)aminophenyl] 
acetyl]oxyacetic acid), a nonsteroidal anti-inflammatory 
drug NSAID) has been indicated for various painful 
indications and proved as effective as other NSAIDs with 
lower indications of gastro-intestinal adverse effects and 
thus, result in a greater compliance with treatment[4]. 
Aceclofenac is practically insoluble. For poorly soluble orally 
administered drugs, the rate of absorption is often 
controlled by the rate of dissolution.[5] In the present study, 
an attempt was made to develop mouth dissolving tablets of 
aceclofenac and to investigate the effect of different 
concentration of super disintegrants on the release profile of 
the drug by using 32 factorial design in design expert 
software. 
MATERIALS AND METHODS 
Materials 
Aceclofenac was gifted by medley pharmaceuticals, 
croscarmellose sodium and avicel ph were  gifted by signet 
chemical Mumbai. Lactose, sodium saccharine, magnesium 
stearate were purchased from S.D Fine Chem. Mumbai. 
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Method used 
Mouth dissolving tablets of Aceclofenac were prepared by 
using two super disintegrants croscarmellose sodium and 
avicel ph, lactose as diluent, sodium saccharin as sweetening 
agent and magnesium stearate as a flow promoter. 
Blending and tableting 
Tablets containing 250 mg of Aceclofenac are prepared by 
dry granulation method and various ingredients used in the 
study are shown in Table 1. The drug, diluents, super 
disintegrants and sweetener are passed through sieve # 40 
and then passed through sieve #20. All the above 
ingredients were properly mixed to obtain coherent mass. 
The powder blend was compressed in to tablets on twelve 
station rotary punch-tableting machine (Karnavati, Rimek 
Mini Press- 2) using 8 mm concave punches set. The 
hardness of tablets was taken between 3 and 4.5 kg/cm2.
 
Table 1: Formulation Table 
S.N. INGREDIENTS F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 Aceclofenac 100 100 100 100 100 100 100 100 100 
2 Cross Carmellose Sodium 12.5 10 7.5 12.5 10 7.5 12.5 10 7.5 
3 Sodium Saccharin 2 2 2 2 2 2 2 2 2 
4 Micro Crystalline Cellulose 35 35 35 30 30 30 25 25 25 
5 Mg Stearate 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 
6 Lactose 86 88.5 91 91 93.5 96 96 98.5 101 
 
RESULTS AND DISCUSSION 
1. Authentication of Drug: 
a. UV Spectrophotometry:The solution of aceclofenac in PBS (pH 7.4) was found to exhibit maximum absorption (λ max) at  276 
nm after scanning in the range of 200-400 nm by UV spectrophotometer. 
 
Fig 1: UV spectrum of Aceclofenac 
b. Fourier transmission infrared (FT-IR) spectroscopy: Identity of the drug was confirmed by comparing IR spectrum of drug with 
reported spectrum of Aceclofenac as shown in Fig. 
 
Fig 2: FT-IR spectrum of Aceclofenac 
 Table 2: IR Frequency range 
Functional groups Ranges 
C-C streching bond 1772 
C=O bond 1718 
C=C bond 1589 
-COOH bond 1590 
-NH bond 1507 
C-Cl bond 748 
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Fig 3: IR spectra of formulation 
Table 3: IR Frequency range 
Functional groups Ranges 
C-C streching bond 1921 
C=O bond 1771 
C=C bond 1590 
-COOH bond 1717 
-NH bond 1510 
C-Cl bond 750 
 
c. Melting point of Drug: Melting point of the drug was determined by capillary method and was found to be approximately 
152±0.5°C. This was within the limits as per literature. This confirms purity of drug substance. 
d. Solubility study: Solubility study was performed in water, ethanol, methanol, chloroform. 
2. Construction of calibration curve: Calibration curve for aceclofenac  drug was determined in PBS (pH 7.4) by UV method. 
 
Fig 4: Calibration curve of aceclofenac 
Table 4: Absorbance values of Aceclofenac 
Concentration (ug/ml) Absorbance 
20 0.107 
40 0.194 
60 0.282 
80 0.383 
100 0.450 
 
3. Drug-Excipients compatibility study  
Compatibility studies of pure drug with superdisintegrants and other excipients were carried out prior to the preparation of 
tablets. The pure drug was mixed with each excipients in the ratio of 1:1 individually. The drug-excipient mixtures were taken 
in the vials which was previously washed, cleaned and completely dried in an oven.  
Table 5: Drug excipients compatibility studies 
Sr No Drug + Excipients Observation Result 
1 Drug + Crosscarmellose sodium White to off white powder Compatible 
2 Drug + Micro crystalline cellulose White to off white powder Compatible 
3 Drug + Lactose White to off white powder Compatible 
4 Drug +Magnesium stearate White to off white powder Compatible 
5 Drug +Sodium saccharine White to off white powder Compatible 
 
y = 0.046x 
R² = 0.992 
0
0.2
0.4
0.6
0 20 40 60 80 100 120
absorbance 
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Linear (abs)
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EVALUATION TEST FOR FAST DISSOLVING TABLET [9-13] 
1. PRE-COMPRESSION PARAMETERS 
Table 6: Precompression evaluation of Aceclofenac mouth dissolving tablets 
Formulation 
 
Angle of 
repose() 
Bulk density 
(g/ml) 
Tapped density 
(g/ml) 
Carr’s Index 
(%) 
Hausner’s 
ratio 
F1 28.59 ± 0.27 0.625 ± 0.023 0.758 ± 0.017 17.55 ± 0.21 1.21 ± 0.03 
F2 26.57 ± 0.35 0.641 ± 0.016 0.758 ± 0.023 15.44 ± 0.14 1.18 ± 0.02 
F3 26.70 ± 0.28 0.610 ± 0.028 0.735 ± 0.028 17.01 ± 0.19 1.20 ± 0.04 
F4 28.32 ± 0.24 0.625 ± 0.017 0.735 ± 0.007 14.97 ± 0.07 1.18 ± 0.06 
F5 26.70 ± 0.18 0.595 ± 0.029 0.694 ± 0.009 14.27 ± 0.08 1.17 ± 0.05 
F6 27.74 ± 0.30 0.610 ± 0.024 0.714 ± 0.020 14.57 ± 0.16 1.17 ± 0.04 
F7 28.59 ± 0.29 0.658 ± 0.014 0.781 ± 0.024 15.75 ± 0.13 1.19 ± 0.02 
F8 28.94 ± 0.17 0.490 ± 0.025 0.595 ± 0.017 17.65 ± 0.09 1.21 ± 0.03 
F9 28.41 ± 0.21 0.481 ± 0.018 0.581 ± 0.008 17.21 ± 0.24 1.21 ± 0.05 
 
Angle of repose 
The angle of repose of the drug powder was in the range of 26.57 ± 0.35 to 28.94 ± 0.17, which indicates good flow of the drug 
powder. 
Bulk density 
Bulk density of the drug powder was found to be in the range of g/ml 0.481 ± 0.018 to0.658 ± 0.014 g/ml. 
Tapped density 
Tapped density of the drug powder was found to be in the range of 0.581 ± 0.008g/ml to 0.781 ± 0.024 g/ml. 
Carr’s compressibility index 
The Carr’s index was found to be in the range of 14.27 ± 0.08% to17.65 ± 0.09 % indicating good flow of the powder blends. 
Hausner ratio 
Haunser’s ratio was found in the range of 1.17 ± 0.04 to 1.21 ± 0.05 indicates good flow of the powder blends. 
2. POST COMPRESSION PARAMETERS. 
Table 7: Post compression evaluation of Aceclofenac mouth dissolving tablets 
Formula
tion 
Thickness 
(mm) 
Diameter (mm) Hardness 
(kg/cm²) 
Weight 
variation (mg) 
Friability (%) Drug 
content 
F1 3.98 ± 0.06 9.06 ± 0.05 2.17 ± 0.29 249.11 ± 3.15 0.765 ± 0.020 88% 
F2 4.06 ± 0.08 9.04 ± 0.07 2.17 ± 0.29 245.78 ± 2.36 0.748 ± 0.009 90% 
F3 4.30 ± 0.12 9.15 ± 0.06 2.17 ± 0.29 242.89 ± 2.68 0.758 ± 0.013 95% 
F4 4.01 ± 0.05 9.04 ± 0.03 2.17 ± 0.29 253.56 ± 1.17 0.753 ± 0.012 90% 
F5 4.19 ± 0.07 9.14 ± 0.02 2.17 ± 0.29 253.78 ± 1.88 0.772 ± 0.010 91% 
F6 4.10 ± 0.08 9.11 ± 0.04 2.17 ± 0.29 252.22 ± 2.35 0.780 ± 0.018 92% 
F7 4.47 ± 0.05 9.03 ± 0.03 2.33 ± 0.29 256.78 ± 1.58 0.776 ± 0.013 94% 
F8 4.33 ± 0.03 9.11 ± 0.01 2.17 ± 0.29 253.44 ± 2.49 0.571 ± 0.017 93% 
F9 4.06 ± 0.10 9.13 ± 0.07 2.17 ± 0.29 251.78 ± 2.48 0.588 ± 0.011 90% 
 
DISINTEGRATION TIME: 
Table 8: Disintegration time 
Batch no  Disintegration time (sec) 
F1 78 
F2 50 
F3 47 
F4 67 
F5 56 
F6 96 
F7 85 
F8 63 
F9 60 
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IN VITRO DISSOLUTION STUDIES 
Table 9: In vitro dissolution Graphs (F1-F9) 
Time 
(mins) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 3 1 1.5 3.2 2 0 0 
5 10 12 15 12.5 20 13.2 16 18.9 20 
10 30 29 31.83 27.23 25 19 30 30 33.5 
15 43.82 30 36.5 33.5 29.2 27 39 42.1 42.5 
30 46.21 57.89 46.69 40.23 39.33 30 47.19 53.22 52.89 
45 53.12 74.56 79.82 53.91 51.9 38 53.11 72.56 68.3 
60 70 93 94 68 69.9 42 69.01 91.63 83 
 
 
Fig 5: Dissolution graph F1-F3 
 
Fig 6: Dissolution graph F4-F6
 
 
Fig 7:  Dissolution graph of F7-F9 
 
RELEASE KINETICS DATA OF OPTIMIZED BATCH: 
Table 10: Release Kinetic Model  
Release Kinetic Model Regression Coefficient (R)2 
Zero  Order 0.923 
First Order 0.979 
Higuchi Model 0.994 
Hixscon-Crowell Model 0.972 
Koresmeyers- Peppas Model 0.808 
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6. TABLET FORMULATION AND DEVELOPMENT BY 
USING 32 FACTORIAL DESIGNS 
The present study consisted of a three-level two-factorial 
(32) design for experimentation. Statistical experimental 
design was performed using a software DESIGN EXPERT® 
version 11 (Stat-Ease Inc., Minneapolis, USA). Response 
surface graphics were used to show the factor interaction 
between the considered variables. Selected independent 
variables studied were the concentration of microcrystaline 
cellulose and croscarmelose sodium in varying 
concentrations viz. (X1) and (X2) respectively. Three factorial 
levels coded for low, medium and high settings (−1, 0 and 1, 
respectively) were considered for two independent 
variables. The selected dependent variables investigated 
were the drug release in 1hrs (Y1) and disintegration time 
(Y2). The number of trials required for the study is based on 
the number of independent variables selected.  A total of 9 
experimental runs were required for analyzing the 
interaction of each level on formulation characters and to 
optimize. [6, 7, 8] 
 
Table 11: Formulation Code 
Formulation 
Code 
X1 X2 Microcrystaline 
cellulose (X1) 
Croscarmelose 
sodium (X2) 
F1 -1 -1 25 7.5 
F2 0 -1 30 7.5 
F3 1 -1 35 7.5 
F4 -1 0 25 10 
F5 0 0 30 10 
F6 1 0 35 10 
F7 -1 1 25 12.5 
F8 0 1 30 12.5 
F9 1 1 35 12.5 
 
Formulation design 
Tablets were made by direct compression method. The 
various batches were prepared by using 2 super 
disintegrants namely avicel ph(microcrystalline cellulose), 
croscarmellose sodium . All the ingredients were passed 
through 40 # and 60# mesh separately. Then the ingredients 
were weighed and mixed in geometrical order and 
compressed into tablets to 250 mg by direct compression 
method by using 8mm flat punch. 
EXPERIMENTAL DESIGN & STATISTICAL ANALYSIS  
ANOVA for Linear model 
Response 1: Dissolution 
 
Table 12: Analysis of variance table of dissolution [Partial sum of squares- Type III] 
Source Sum of Squares df Mean Square F-value p-value  
Model 2167.15 2 1083.57 27.68 < 0.0001 significant 
A-MCC 373.83 1 373.83 9.55 0.0114  
B-S.D 1793.32 1 1793.32 45.82 < 0.0001  
Residual 391.42 10 39.14    
Lack of Fit 391.42 6 65.24    
Pure Error 0.0000 4 0.0000    
Cor Total 2558.56 12     
 
Factor coding is Coded. 
Sum of squares is Type III - Partial 
The Model F-value of 27.68 implies the model is significant. 
There is only a 0.01% chance that an F-value this large could 
occur due to noise. P-values less than 0.0500 indicate model 
terms are significant. In this case A, B are significant model 
terms. Values greater than 0.1000 indicate the model terms 
are not significant. 
                  
 
Fig 8: Interaction plot                                                    Fig 9: 3D plot 
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Fig 10: Counter plot 
Response 2: Disintigration time 
Table 13: Analysis of variance  
Source Sum of Squares df Mean Square F-value p-value  
Model 216.67 2 108.33 112.37 < 0.0001 significant 
A-MCC 66.67 1 66.67 69.15 < 0.0001  
B-CCS 150.00 1 150.00 155.59 < 0.0001  
Residual 9.64 10 0.9641    
Lack of Fit 9.64 6 1.61    
Pure Error 0.0000 4 0.0000    
Cor Total 226.31 12     
 
Factor coding is Coded. 
Sum of squares is Type III - Partial 
The Model F-value of 112.37 implies the model is 
significant. There is only a 0.01% chance that an F-value this 
large could occur due to noise. 
P-values less than 0.0500 indicate model terms are 
significant. In this case A and B are significant model terms. 
Values greater than 0.1000 indicate the model terms are not 
significant. If there are many insignificant model terms (not 
counting those required to support hierarchy), model 
reduction may improve your model. 
 
 
Fig 11: Interaction Plot                                        Fig 12: 3D Plot 
 
Fig 13: Contour plot 
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CONCLUSION 
1. Aceclofenac Mouth dissolving tablets were prepared by using 
Cross carmellose sodium and Micro crystalline cellulose as 
superdisintgrants, Lactose as Diluent, Magnesium stearate as 
flowing aid and sodium saccharin as sweetner.  
2. Aceclofenac MDT was prepared for fast release and quick 
action for inflammatory conditions. 
3. The optimized batch followed Higuchi model for release 
kinetics. 
4. In conclusion, it is suggested that Aceclofenac MDT with 
crosscarmellose sodium and avicel ph can be a better option 
in inflammatory conditions. 
5. It was concluded that fast disintegrating tablets of 
Aceclofenac can be successfully prepared using selected 
superdisitegrants in order to improve 
disintegration/dissolution of the drug in oral cavity and hence 
better patient compliance and effective therapy. 
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